Represented Oklahoma Medical Research Foundation (OMRF) in a suit against Eli Lilly in the Western District of Oklahoma. OMRF alleged patent infringement and breach of a license agreement in connection with Eli Lilly's sales of Xigris, the first FDA-approved drug to treat severe sepsis. The suit settled on the eve of trial after more than 60 depositions, production of more than one million pages of documents by Eli Lilly, and a Markman hearing resulting in a claim construction favorable to our client.

Oklahoma Med. Research Found. v. Eli Lilly & Co., No. 01-0456 (W.D. Okla. filed Mar. 15, 2001).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Public-private partnership for private development of a large U.S. public school system
Represented one of the 25 largest U.S. public school systems in a public-private partnership for the private development of public schools. more
Formation of real estate investment funds for real estate investment, development and finance company
Represented a real estate investment, development and finance company in the formation and securities offering of six real estate investment funds. more
Sara Lee Corp. v. Kayser-Roth Corp.
Represented Sara Lee Corporation, makers of L’EGGS hosiery, as plaintiff against one of its major competitors in a trademark and trade dress more
In re: Teflon products liability litigation
Jointly represented DuPont in the Teflon multi-district litigation. In that case, two dozen putative classes of consumer plaintiffs sought recovery more